Back

Tectonic Therapeutic reports promising Phase 1b data for TX45

Verifying
  • Tectonic Therapeutic reported promising Phase 1b data for its TX45 drug.
  • TX45 targets pulmonary hypertension in patients with heart failure.
  • Merck trial results support the program, while Tectonic has cash to fund operations.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.